Patients’ Preferences regarding the Timing of Highly Active Antiretroviral Therapy Initiation for Chronic Asymptomatic HIV-1 Infection
- 1 April 2006
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 11 (3) , 335-341
Abstract
Objective: In patients with a chronic asymptomatic HIV-1 infection and >200 CD4 + T-cells/μl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earlier exposure to pill burden and potential toxicities. We investigated patients’ preferences for immediate HAART initiation relative to delaying HAART for 1 year. Methods: Consecutive patients were asked for their preference during an interview. A hypothetical difference in 3-year mortality risk between both options was systematically varied between 0% and 10% to determine the threshold at which preference would switch to HAART initiation. Results: About 30% of patients preferred HAART initiation even if the mortality risk would be equal for both options. Almost 25% always preferred delaying HAART even if this would result in a 10% greater mortality risk. Most treatment guidelines recommend delaying HAART >350 CD4 + T-cells/μl However, at a risk difference between starting and delaying HAART that corresponds with this CD4 + T-cell count, about 50% would prefer to start HAART immediately. Most guidelines recommend starting HAART below 200 CD4 + T-cells/μl However, at a risk difference between both options corresponding with this CD4 + T-cell count, about 40% preferred delaying HAART. Conclusions: We found large variation in patients’ preferences. Some patients were more inclined to initiate HAART earlier than the recommended guidelines, whereas others were more inclined to delay HAART. These findings emphasize the need for shared decision-making when deciding on the most optimal timing of HAART initiation in chronic asymptomatic HIV-1 infection.Keywords
This publication has 22 references indexed in Scilit:
- Mortality in HIV‐Seropositive versus ‐Seronegative Persons in the Era of Highly Active Antiretroviral Therapy: Implications for When to Initiate TherapyThe Journal of Infectious Diseases, 2004
- Review of Determinants of Patients’ Preferences for Adjuvant Therapy in CancerJournal of Clinical Oncology, 2004
- Treatment for Adult HIV InfectionJAMA, 2004
- Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/lAIDS, 2002
- Perceptions of HAART among gay men who declined a treatment offer: Preliminary results from an interview-based studyAIDS Care, 2002
- Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational studyCommentary: Varied preferences reflect the reality of clinical practiceBMJ, 2001
- How do patients' treatment preferences compare with those of clinicians?Quality and Safety in Health Care, 2001
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Incorporating Patients' Preferences into Medical DecisionsNew England Journal of Medicine, 1994